<p>根据 Causeway Capital Management LLC 最近向 SEC 提交的 Form 13F 文件，该公司在第三季度减少了对 Smith &amp; Nephew SNATS, Inc.（NYSE:SNN - 免费报告）股票的持股比例，降幅为 30.3%。该基金在此期间出售了 248,476 股后，持有 572,532 股该医疗设备提供商的股票。截至最近的 SEC 文件，Causeway Capital Management LLC 持有的 Smith &amp; Nephew SNATS 股票约占 0.13%，价值 20,777,000 美元。</p>
<p>获取 <strong>Smith &amp; Nephew SNATS</strong> 警报：</p>
<ul>
<li>圣诞节行情提前到来，影响这些股票</li>
</ul>
<p>其他一些对冲基金和机构投资者最近也增加或减少了对 SNN 的持股。摩根大通在第二季度将对 Smith &amp; Nephew SNATS 的持股增加了 6,663.4%。摩根大通现在持有 1,210,655 股该医疗设备提供商的股票，价值 37,082,000 美元，此前在此期间又购买了 1,192,755 股。ABC Arbitrage SA 在第二季度将对 Smith &amp; Nephew SNATS 的持股增加了 1,063.4%。ABC Arbitrage SA 现在持有 898,635 股该医疗设备提供商的股票，价值 27,525,000 美元，此前在上个季度又购买了 821,393 股。Todd Asset Management LLC 在第三季度购买了 Smith &amp; Nephew SNATS 的新头寸，估计价值约为 26,319,000 美元。高盛集团在第一季度将对 Smith &amp; Nephew SNATS 的持股增加了 49.2%。高盛集团现在持有 1,771,401 股该医疗设备提供商的股票，价值 50,255,000 美元，此前在上个季度又购买了 583,809 股。最后，法国巴黎银行金融市场在第二季度将对 Smith &amp; Nephew SNATS 的持股增加了 365.1%。法国巴黎银行金融市场现在持有 644,525 股该医疗设备提供商的股票，价值 19,742,000 美元，此前在上个季度又收购了 505,934 股。目前，25.64% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Smith &amp; Nephew SNATS 股价下跌 0.8%</h2>
<p>周二，SNN 股票开盘价为 34.03 美元。该股票的 50 日移动平均线为 34.45 美元，200 日移动平均线为 34.89 美元。Smith &amp; Nephew SNATS, Inc.的 52 周低点为 23.91 美元，52 周高点为 38.79 美元。该公司的速动比率为 1.25，流动比率为 2.57，债务与股本比率为 0.60。</p>
<h2>Smith &amp; Nephew SNATS 分红公告</h2>
<ul>
<li>外科中心、医疗科技股票因手术需求积压而上涨</li>
</ul>
<p>该公司最近宣布了一项分红，将于 5 月 27 日（星期三）支付。3 月 27 日（星期五）登记的投资者将获得每股 0.482 美元的分红。除息日期为 3 月 27 日（星期五）。这代表着 281.0% 的分红收益率。</p>
<h2>华尔街分析师预测增长</h2>
<p>多位股票分析师对该股票发表了评论。Weiss Ratings 在 1 月 21 日（星期三）的研究报告中重新发布了对 Smith &amp; Nephew SNATS 的 “持有（c+）” 评级。Kepler Capital Markets 在 11 月 17 日（星期一）的研究报告中将 Smith &amp; Nephew SNATS 的评级提升至 “强力买入”。Wall Street Zen 在周六的研究报告中将 Smith &amp; Nephew SNATS 的评级从 “买入” 升级为 “强力买入”。Canaccord Genuity Group 在 3 月 5 日（星期四）的研究报告中将 Smith &amp; Nephew SNATS 的目标价从 34.00 美元提升至 35.00 美元，并给予该股票 “持有” 评级。最后，加拿大皇家银行在 12 月 15 日（星期一）的报告中将 Smith &amp; Nephew SNATS 的评级从 “跑赢大盘” 下调至 “行业表现”。一位投资分析师对该股票给予了强力买入评级，五位分析师对该公司给予了持有评级。根据 MarketBeat 的数据，Smith &amp; Nephew SNATS 目前的平均评级为 “持有”，共识目标价为 36.25 美元。</p>
<ul>
<li>三只医疗保健分红股票，价格增长显著</li>
</ul>
<p><strong>阅读我们关于 Smith &amp; Nephew SNATS 的最新报告</strong></p>
<h2>Smith &amp; Nephew SNATS 公司简介</h2>
<p>（免费报告）</p>
<p>Smith &amp; Nephew plc 是一家全球医疗技术公司，专注于先进外科设备、骨科重建植入物、创伤和四肢产品、运动医学解决方案以及伤口护理疗法的设计、开发和制造。该公司成立于 1856 年，总部位于英国赫尔，通过有机创新和战略收购不断发展，提供广泛的产品组合，以满足关节置换、微创手术和伤口愈合等患者需求。</p>
<p>在其骨科业务中，Smith &amp; Nephew 提供髋关节和膝关节置换系统、模块化关节修复植入物以及骨修复的生物解决方案。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Smith &amp; Nephew SNATS</li>
<li>市场刚刚分裂为两部分（紧急）</li>
<li>在 2026 年 5 月 15 日之前购买这只黄金股票</li>
<li>摩根大通正在押注这种货币</li>
<li>中央银行刚刚做了一件自 1967 年以来未曾做过的事情</li>
<li>股票代码揭晓：预 IPO 获取 “下一个埃隆·马斯克” 公司的机会</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNOTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNOTg"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Smith &amp; Nephew SNATS 吗？</h2>
<p>在考虑 Smith &amp; Nephew SNATS 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Smith &amp; Nephew SNATS 并不在名单上。</p>
<p>虽然 Smith &amp; Nephew SNATS 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

<p>Causeway Capital Management LLC 将其在 Smith & Nephew SNATS, Inc. 的持股减少了 30.3%，在第三季度出售了 248,476 股，目前持有 572,532 股，价值 2080 万美元。其他机构投资者，包括摩根大通和高盛，也显著调整了他们的持仓。Smith & Nephew 的股票开盘价为 34.03 美元，52 周价格区间为 23.91 美元至 38.79 美元。该公司宣布每股派息 0.482 美元，收益率为 281.0%。分析师的评级意见不一，平均共识为 “持有”，目标价为 36.25 美元</p>

<p>Causeway Capital Management LLC lessened its stake in shares of Smith &amp; Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 30.3% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 572,532 shares of the medical equipment provider's stock after selling 248,476 shares during the period. Causeway Capital Management LLC owned about 0.13% of Smith &amp; Nephew SNATS worth $20,777,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>根据 Causeway Capital Management LLC 最近向 SEC 提交的 Form 13F 文件，该公司在第三季度减少了对 Smith &amp; Nephew SNATS, Inc.（NYSE:SNN - 免费报告）股票的持股比例，降幅为 30.3%。该基金在此期间出售了 248,476 股后，持有 572,532 股该医疗设备提供商的股票。截至最近的 SEC 文件，Causeway Capital Management LLC 持有的 Smith &amp; Nephew SNATS 股票约占 0.13%，价值 20,777,000 美元。</p>
</div><p>Get <strong>Smith &amp; Nephew SNATS</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Smith &amp; Nephew SNATS</strong> 警报：</p>
</div><ul>
<li>Santa Rally comes early for these stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>圣诞节行情提前到来，影响这些股票</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SNN. JPMorgan Chase &amp; Co. raised its holdings in shares of Smith &amp; Nephew SNATS by 6,663.4% in the 2nd quarter. JPMorgan Chase &amp; Co. now owns 1,210,655 shares of the medical equipment provider's stock worth $37,082,000 after purchasing an additional 1,192,755 shares during the period. ABC Arbitrage SA lifted its holdings in Smith &amp; Nephew SNATS by 1,063.4% during the 2nd quarter. ABC Arbitrage SA now owns 898,635 shares of the medical equipment provider's stock worth $27,525,000 after purchasing an additional 821,393 shares in the last quarter. Todd Asset Management LLC purchased a new position in Smith &amp; Nephew SNATS during the third quarter valued at approximately $26,319,000. Goldman Sachs Group Inc. grew its position in shares of Smith &amp; Nephew SNATS by 49.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider's stock valued at $50,255,000 after purchasing an additional 583,809 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its stake in Smith &amp; Nephew SNATS by 365.1% in the 2nd quarter. BNP Paribas Financial Markets now owns 644,525 shares of the medical equipment provider's stock worth $19,742,000 after acquiring an additional 505,934 shares during the last quarter. 25.64% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他一些对冲基金和机构投资者最近也增加或减少了对 SNN 的持股。摩根大通在第二季度将对 Smith &amp; Nephew SNATS 的持股增加了 6,663.4%。摩根大通现在持有 1,210,655 股该医疗设备提供商的股票，价值 37,082,000 美元，此前在此期间又购买了 1,192,755 股。ABC Arbitrage SA 在第二季度将对 Smith &amp; Nephew SNATS 的持股增加了 1,063.4%。ABC Arbitrage SA 现在持有 898,635 股该医疗设备提供商的股票，价值 27,525,000 美元，此前在上个季度又购买了 821,393 股。Todd Asset Management LLC 在第三季度购买了 Smith &amp; Nephew SNATS 的新头寸，估计价值约为 26,319,000 美元。高盛集团在第一季度将对 Smith &amp; Nephew SNATS 的持股增加了 49.2%。高盛集团现在持有 1,771,401 股该医疗设备提供商的股票，价值 50,255,000 美元，此前在上个季度又购买了 583,809 股。最后，法国巴黎银行金融市场在第二季度将对 Smith &amp; Nephew SNATS 的持股增加了 365.1%。法国巴黎银行金融市场现在持有 644,525 股该医疗设备提供商的股票，价值 19,742,000 美元，此前在上个季度又收购了 505,934 股。目前，25.64% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Smith &amp; Nephew SNATS Trading Down 0.8%</h2>
<div class="lb-trans"><h2>Smith &amp; Nephew SNATS 股价下跌 0.8%</h2>
</div><p>Shares of SNN stock opened at $34.03 on Tuesday. The stock has a fifty day moving average of $34.45 and a 200 day moving average of $34.89. Smith &amp; Nephew SNATS, Inc. has a 52 week low of $23.91 and a 52 week high of $38.79. The company has a quick ratio of 1.25, a current ratio of 2.57 and a debt-to-equity ratio of 0.60.</p>
<div class="lb-trans"><p>周二，SNN 股票开盘价为 34.03 美元。该股票的 50 日移动平均线为 34.45 美元，200 日移动平均线为 34.89 美元。Smith &amp; Nephew SNATS, Inc.的 52 周低点为 23.91 美元，52 周高点为 38.79 美元。该公司的速动比率为 1.25，流动比率为 2.57，债务与股本比率为 0.60。</p>
</div><h2>Smith &amp; Nephew SNATS Dividend Announcement</h2>
<div class="lb-trans"><h2>Smith &amp; Nephew SNATS 分红公告</h2>
</div><ul>
<li>Surgical Centers, Med-Tech Stocks Up On Pent-Up Surgical Demand</li>
</ul>
<div class="lb-trans"><ul>
<li>外科中心、医疗科技股票因手术需求积压而上涨</li>
</ul>
</div><p>The business also recently declared a dividend, which will be paid on Wednesday, May 27th. Investors of record on Friday, March 27th will be given a dividend of $0.482 per share. The ex-dividend date is Friday, March 27th. This represents a dividend yield of 281.0%.</p>
<div class="lb-trans"><p>该公司最近宣布了一项分红，将于 5 月 27 日（星期三）支付。3 月 27 日（星期五）登记的投资者将获得每股 0.482 美元的分红。除息日期为 3 月 27 日（星期五）。这代表着 281.0% 的分红收益率。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of equities analysts have commented on the stock. Weiss Ratings reissued a &#34;hold (c+)&#34; rating on shares of Smith &amp; Nephew SNATS in a research note on Wednesday, January 21st. Kepler Capital Markets raised Smith &amp; Nephew SNATS to a &#34;strong-buy&#34; rating in a research note on Monday, November 17th. Wall Street Zen upgraded Smith &amp; Nephew SNATS from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday. Canaccord Genuity Group lifted their price target on shares of Smith &amp; Nephew SNATS from $34.00 to $35.00 and gave the stock a &#34;hold&#34; rating in a research note on Thursday, March 5th. Finally, Royal Bank Of Canada lowered shares of Smith &amp; Nephew SNATS from an &#34;outperform&#34; rating to a &#34;sector perform&#34; rating in a report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, Smith &amp; Nephew SNATS currently has an average rating of &#34;Hold&#34; and a consensus price target of $36.25.</p>
<div class="lb-trans"><p>多位股票分析师对该股票发表了评论。Weiss Ratings 在 1 月 21 日（星期三）的研究报告中重新发布了对 Smith &amp; Nephew SNATS 的 “持有（c+）” 评级。Kepler Capital Markets 在 11 月 17 日（星期一）的研究报告中将 Smith &amp; Nephew SNATS 的评级提升至 “强力买入”。Wall Street Zen 在周六的研究报告中将 Smith &amp; Nephew SNATS 的评级从 “买入” 升级为 “强力买入”。Canaccord Genuity Group 在 3 月 5 日（星期四）的研究报告中将 Smith &amp; Nephew SNATS 的目标价从 34.00 美元提升至 35.00 美元，并给予该股票 “持有” 评级。最后，加拿大皇家银行在 12 月 15 日（星期一）的报告中将 Smith &amp; Nephew SNATS 的评级从 “跑赢大盘” 下调至 “行业表现”。一位投资分析师对该股票给予了强力买入评级，五位分析师对该公司给予了持有评级。根据 MarketBeat 的数据，Smith &amp; Nephew SNATS 目前的平均评级为 “持有”，共识目标价为 36.25 美元。</p>
</div><ul>
<li>3 Healthcare Dividend Payers With Big Price Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>三只医疗保健分红股票，价格增长显著</li>
</ul>
</div><p><strong>Read Our Latest Report on Smith &amp; Nephew SNATS</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Smith &amp; Nephew SNATS 的最新报告</strong></p>
</div><h2>Smith &amp; Nephew SNATS Profile</h2>
<div class="lb-trans"><h2>Smith &amp; Nephew SNATS 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Smith &amp; Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.</p>
<div class="lb-trans"><p>Smith &amp; Nephew plc 是一家全球医疗技术公司，专注于先进外科设备、骨科重建植入物、创伤和四肢产品、运动医学解决方案以及伤口护理疗法的设计、开发和制造。该公司成立于 1856 年，总部位于英国赫尔，通过有机创新和战略收购不断发展，提供广泛的产品组合，以满足关节置换、微创手术和伤口愈合等患者需求。</p>
</div><p>In its orthopaedics business, Smith &amp; Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.</p>
<div class="lb-trans"><p>在其骨科业务中，Smith &amp; Nephew 提供髋关节和膝关节置换系统、模块化关节修复植入物以及骨修复的生物解决方案。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Smith &amp; Nephew SNATS</li>
<li>The Market Just Split in Two (URGENT)</li>
<li>Buy this Gold Stock Before May 15th, 2026</li>
<li>J.P. Morgan is betting on this coin</li>
<li>Central banks just did something they haven’t done since 1967</li>
<li>Ticker Revealed: Pre-IPO Access to &#34;Next Elon Musk&#34; Company</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Smith &amp; Nephew SNATS</li>
<li>市场刚刚分裂为两部分（紧急）</li>
<li>在 2026 年 5 月 15 日之前购买这只黄金股票</li>
<li>摩根大通正在押注这种货币</li>
<li>中央银行刚刚做了一件自 1967 年以来未曾做过的事情</li>
<li>股票代码揭晓：预 IPO 获取 “下一个埃隆·马斯克” 公司的机会</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNOTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=SNN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Smith &amp; Nephew SNATS Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Smith &amp; Nephew SNATS 吗？</h2>
</div><p>Before you consider Smith &amp; Nephew SNATS, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Smith &amp; Nephew SNATS 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith &amp; Nephew SNATS wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Smith &amp; Nephew SNATS 并不在名单上。</p>
</div><p>While Smith &amp; Nephew SNATS currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Smith &amp; Nephew SNATS 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Causeway Capital Management LLC 出售了 Smith and Nephew SNATS, Inc. $SNN 的 248,476 股股票